Reay MD - Sight Sciences Chief Officer
| SGHT Stock | USD 2.98 0.10 3.47% |
Executive
Reay MD is Chief Officer of Sight Sciences
| Address | 4040 Campbell Avenue, Menlo Park, CA, United States, 94025 |
| Phone | 877 266 1144 |
| Web | https://www.sightsciences.com |
Sight Sciences Management Efficiency
The company has return on total asset (ROA) of (0.2041) % which means that it has lost $0.2041 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4959) %, meaning that it created substantial loss on money invested by shareholders. Sight Sciences' management efficiency ratios could be used to measure how well Sight Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.38 in 2025. Return On Capital Employed is likely to drop to -0.42 in 2025. At this time, Sight Sciences' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 46.7 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 12.3 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Lucas Vitale | Orthofix Medical | 47 | |
| Daniel Cher | Si Bone | 60 | |
| Matthew Brinckman | Paragon 28 | N/A | |
| Sigfrido Delgado | Avanos Medical | 48 | |
| Jennifer Englund | CVRx Inc | N/A | |
| Martha MD | Neuropace | 68 | |
| John Shumaker | Paragon 28 | N/A | |
| John Ferrell | CONMED | 56 | |
| Scott Galovan | Avanos Medical | N/A | |
| Lee Burnes | Avanos Medical | N/A | |
| Katie Keller | Neuropace | N/A | |
| Aaron Snodgrass | Tactile Systems Technology | N/A | |
| Michael Pisetsky | Si Bone | 46 | |
| Peter Schaubach | Tactile Systems Technology | N/A | |
| Jill Mason | Orthofix Medical | N/A | |
| Lisa Funiciello | Anika Therapeutics | N/A | |
| Roberto Donadello | Orthofix Medical | N/A | |
| Sean CPA | Rapid Micro Biosystems | 56 | |
| Andres Cedron | Orthofix Medical | 44 | |
| John Hurley | Avanos Medical | N/A | |
| Jrme Erath | Pulmonx Corp | N/A | |
Management Performance
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.2 |
Sight Sciences Leadership Team
Elected by the shareholders, the Sight Sciences' board of directors comprises two types of representatives: Sight Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sight. The board's role is to monitor Sight Sciences' management team and ensure that shareholders' interests are well served. Sight Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sight Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA BS, VP Operations | ||
| Stacie Rodgers, VP HR | ||
| John Liu, VP Access | ||
| Stephen JD, Secretary | ||
| Reay MD, Chief Officer | ||
| Sam Park, Chief Officer | ||
| John Ordway, VP Operations | ||
| Brenton Taylor, Executive Operations | ||
| Jim Rodberg, VP Controller | ||
| Matthew Link, Chief Officer | ||
| Jeremy JD, Chief Officer | ||
| Paul Badawi, President, CoFounder | ||
| Steve Tamayo, VP Officer | ||
| Tom Huang, Head Development | ||
| Alison Bauerlein, CFO Treasurer | ||
| Reay Brown, Chief Officer | ||
| David MD, CTO CoFounder | ||
| Jesse Selnick, Chief Officer | ||
| Jeremy Hayden, Chief Officer | ||
| Manohar Raheja, Executive Development |
Sight Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sight Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (0.64) % | ||||
| Operating Margin | (0.63) % | ||||
| Current Valuation | 67.84 M | ||||
| Shares Outstanding | 51.33 M | ||||
| Shares Owned By Insiders | 20.59 % | ||||
| Shares Owned By Institutions | 54.76 % | ||||
| Number Of Shares Shorted | 1.41 M | ||||
| Price To Book | 1.69 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sight Stock Analysis
When running Sight Sciences' price analysis, check to measure Sight Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sight Sciences is operating at the current time. Most of Sight Sciences' value examination focuses on studying past and present price action to predict the probability of Sight Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sight Sciences' price. Additionally, you may evaluate how the addition of Sight Sciences to your portfolios can decrease your overall portfolio volatility.